Progenics Pharma (PGNX) Tops Q4 EPS by 4c

Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• AMC Entertainment launches tender offer for $360M in senior notes
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)